This page can be accessed at http://www.oecd.org/futures/bioeconomy/2030
The biological sciences are adding value to a host of products and services, producing what some have labelled the “bioeconomy”. From a broad economic perspective, the bioeconomy refers to the set of economic activities relating to the invention, development, production and use of biological products and processes. If it continues on course, the bioeconomy could make major socioeconomic contributions in OECD and non-OECD countries. These benefits are expected to improve health outcomes, boost the productivity of agriculture and industrial processes, and enhance environmental sustainability. The bioeconomy’s success is not, however, guaranteed: harnessing its potential will require coordinated policy action by governments to reap the benefits of the biotechnology revolution.
The Bioeconomy to 2030: Designing a Policy Agenda begins with an evidence-based technology approach, focusing on biotechnology applications in primary production, health, and industry. It describes the current status of biotechnologies and, using quantitative analyses of data on development pipelines and R&D expenditures from private and public databases, it estimates biotechnological developments to 2015. Moving to a broader institutional view, it also looks at the roles of R&D funding, human resources, intellectual property, and regulation in the bioeconomy, as well as at possible developments that could influence emerging business models. Fictional scenarios to 2030 are included to encourage readers to reflect on the interplay between policy choices and technological advances in shaping the bioeconomy. Finally, the book explores policy options to support the social, environmental and economic benefits of a bioeconomy.
The International Futures Programme (IFP) of the OECD undertook The Bioeconomy to 2030 project with the support of other interested OECD directorates, OECD Government Ministries, and outside partners. A number of documents prepared within the context of “The Bioeconomy to 2030” project, including scenarios and analytical reports covering business models, ethics, intellectual property, and regulation are available here .
Both OECD and developing countries face a range of environmental, social, and economic challenges over the next two decades. Rising incomes, particularly in developing countries, will increase demand for healthcare and for agricultural, forestry, and fishing products. At the same time, many of the world’s ecosystems that support human societies are overexploited and unsustainable. Climate change could exacerbate these environmental problems by adversely affecting water supplies and increasing the frequency of drought.
Biotechnology offers technological solutions for many of the health and resource-based problems facing the world. The application of biotechnology to primary production, health and industry could result in an emerging “bioeconomy” where biotechnology contributes to a significant share of economic output. The bioeconomy in 2030 is likely to involve three elements: advanced knowledge of genes and complex cell processes, renewable biomass, and the integration of biotechnology applications across sectors. This book evaluates existing evidence and the characteristics of biotechnology innovation in order to estimate what the bioeconomy of 2030 might look like. It also develops a policy agenda to help guide the use of biotechnology to address current and future challenges. Top
Several factors will drive the emerging bioeconomy by creating opportunities for investment. A major factor is increasing population and per capita income, particularly in developing countries. The global population is expected to reach 8.3 billion in 2030, with 97% of the growth occurring in developing countries. GDP is expected to grow by 4.6% per year in developing countries and by 2.3% in OECD countries. These trends in population and income, combined with rapid increases in educational achievement in China and India, indicate not only that the bioeconomy will be global, but that the main markets for biotechnology in primary production (agriculture, forestry and fishing) and industry could be in developing countries. Increases in energy demand, especially if combined with measures to reduce greenhouse gases, could create large markets for biofuels.
An expected increase in elderly populations, both in China and in OECD countries, will increase the need for therapies to treat chronic and neurodegenerative diseases, some of which will be based on biotechnology. Many countries and healthcare providers will try to reverse rapidly increasing healthcare costs. Biotechnology provides possible solutions to reduce the cost of pharmaceutical R&D and manufacturing. Alternatively, biotechnology could improve the cost-effectiveness of health therapy, so that expensive treatments provide commensurate and significant improvements to health and the quality of life. Top
Biotechnology today is used in primary production, health and industry. Platform technologies such as genetic modification, DNA sequencing, bioinformatics and metabolic pathway engineering have commercial uses in several application fields. The main current uses of biotechnology in primary production are for plant and animal breeding and diagnostics, with a few applications in veterinary medicine. Human health applications include therapeutics, diagnostics, pharmacogenetics to improve prescribing practices, functional foods and nutraceuticals, and some medical devices. Industrial applications include the use of biotechnological processes to produce chemicals, plastics, and enzymes, environmental applications such as bioremediation and biosensors, methods to reduce the environmental effects or costs of resource extraction, and the production of biofuels. Several applications, such as biopharmaceuticals, in vitro diagnostics, some types of genetically modified crops, and enzymes are comparatively “mature” technologies. Many other applications have limited commercial viability without government support (e.g. biofuels and biomining) or are still in the experimental stage, such as regenerative medicine and health therapies based on RNA interference. Top
What types of biotechnology applications are likely to reach the market by 2015? Regulatory requirements in agriculture and health provide data that can be used to estimate the types of genetically modified (GM) plant varieties and health therapies that will be available by then. There are far less data for other biotechnology applications, with estimates based on past trends in scientific discoveries, production, or employment.
Based on past trends, GM field trial data, and company reports, it is estimated that by 2015 approximately half of global production of the major food, feed and industrial feedstock crops is likely to come from plant varieties developed using one or more types of biotechnology. These biotechnologies include not only GM but also intragenics, gene shuffling and marker assisted selection. Several novel agronomic and product quality traits will reach the market for a growing number of crops. Biotechnologies, other than GM, will be used to improve livestock for dairy and meat. GM will be increasingly used to develop animal varieties that can produce valuable pharmaceuticals or other compounds in milk. In health, biotechnological knowledge will play a role in the development of all types of therapies. It will no longer be meaningful to separate the pharmaceutical sector from the health biotechnology sector. Pharmacogenetics will develop rapidly, influencing the design of clinical trials and prescribing practices. The value of biochemicals (other than pharmaceuticals) could increase from 1.8% of all chemical production in 2005 to between 12% and 20% by 2015. Biofuel production could partly shift from starch-based bioethanol to higher energy density fuels manufactured from sugar cane or to bioethanol from lignocellulosic feedstock such as grasses and wood. Top
The emerging bioeconomy will be influenced by public research support, regulations, intellectual property rights, and social attitudes. In 2005, public R&D expenditures within the OECD area for all types of biotechnology were USD 28.7 billion, compared to 2003 R&D expenditures by the private sector of USD 21.5 billion. The public sector is a major player in health biotechnology and accounts for a notable share of research for primary production, with 20% of field trials for genetically modified (GM) crops between 1989 and 2007 conducted by universities or government research institutes. Data on public research support for industrial biotechnology are not available, with the exception of biofuels. Here, most support appears to go to pilot plants instead of to R&D.
Regulations to ensure the safety and efficacy of biotechnology products influence the types of research that are commercially viable and research costs. Pure regulatory costs are highest for GM crops (ranging from USD 0.4 million to USD 13.5 million per variety) and for the open release of GM micro-organisms (approximately USD 3 million per release). The European Union’s de facto moratorium on the commercial production of GM crops appears to have hampered GM research in Europe. In health, the future of regulation is not clear, with economic pressures and technical opportunities pushing the system in different directions. Intellectual property rights could be increasingly used to encourage knowledge sharing through collaborative mechanisms such as patent pools or research consortia. Social attitudes to biotechnology will continue to influence market opportunities, but public opinion can change, for instance when biotechnology products provide significant benefits for consumers or the environment. Top
Social, economic and technological factors will create new business opportunities for biotechnology, requiring new types of business models. The main business models to date have been the small, dedicated biotechnology firm (DBF) that specialises in research and sells knowledge to large firms, and the large integrated firm that performs R&D and manufactures and distributes products. This structure characterises the health sector. In primary production, gene modification technology has created economies of scope and scale that have driven rapid corporate concentration. Only a few DBFs have been active in industrial biotechnology, as profitability depends on the ability to scale up production. This requires specialised engineering knowledge and large capital investment.
This chapter identifies two business models that could emerge in the future: collaborative models for sharing knowledge and reducing research costs, and integrator models to create and maintain markets. Collaborative models are relevant to all application areas. Their adoption, combined with new business opportunities for non-food biomass crops, could revitalise DBFs in primary production and in industry. Integrator models could develop in health biotechnology to manage the complexity of predictive and preventive medicine, based on biomarkers, pharmacogenetics, shrinking markets for individual drugs, and the analysis of complex health databases. Top
What is the bioeconomy of 2030 likely to look like? This chapter describes a “probable” bioeconomy in 2030 and develops two fictional scenarios that explore the interaction of different factors on possible futures. The “probable” bioeconomy builds on the types of products that are likely to reach the market by 2015. Within the OECD region, biotechnology could contribute to 2.7% of GDP in 2030, with the largest economic contribution of biotechnology in industry and in primary production. The economic contribution of biotechnology could be even greater in developing countries, due to the importance of these two sectors to their economies.
The scenarios assume an increasingly multi-polar world, with no single country or region dominating world affairs. They include plausible events that could influence the emerging bioeconomy. The results highlight the importance of good governance, including international cooperation, and technological competitiveness in influencing the future. Complex scientific challenges and poorly designed regulations could reduce the ability of industrial biotechnologies to compete with other alternatives. For instance, rapid reductions in the cost of renewable electricity combined with technical breakthroughs in battery technology could result in electrical vehicles out-competing biofuel transport systems. Public attitudes could result in some biotechnologies not reaching their potential. An example is predictive and preventive medicine, where the advance of this technology could be limited by public resistance to poorly planned and intrusive healthcare systems. Top
The social and economic benefits of the bioeconomy will depend on good policy decisions. The required mix of policies is linked to the potential economic impacts of biotechnological innovations on the wider economy. Each type of innovation can have incremental, disruptive or radical effects. In many (but not all) cases incremental innovations fit well within existing economic and regulatory structures. Disruptive and radical innovations can lead to the demise of firms and industrial structures, creating greater policy challenges, but they can also result in large improvements in productivity. This chapter identifies policy options to address challenges in primary production, health and industrial biotechnology. It also looks at cross-cutting issues for intellectual property and for knowledge spillovers and integration, global challenges, and the need to develop policies over both the short and long term.
Primary production provides a diverse range of policy challenges. Examples include the need to simplify regulation, encourage the use of biotechnology to improve the nutritional content of staple crops in developing countries, ensure unhindered trade in agricultural commodities, and manage a decline in the economic viability of cool-climate forestry resources for low value commodities such as pulp and paper. The main challenges for health applications are to better align private incentives for developing health therapies with public health goals and to manage a transition to regenerative medicine and predictive and preventive medicine, both of which could disrupt current healthcare systems. Industrial biotechnology faces multiple futures due to competitive alternatives from both outside and within biotechnology. Policy needs to flexibly adapt to different outcomes and prevent “lock-in” to inferior technological solutions. Top
Obtaining the full benefits of the bioeconomy will require purposive goal-oriented policy. This will require leadership, primarily by governments but also by leading firms, to establish goals for the application of biotechnology to primary production, industry and health; to put in place the structural conditions required to achieve success such as obtaining regional and international agreements; and to develop mechanisms to ensure that policy can flexibly adapt to new opportunities. There are nine main challenges, summarised in this chapter. Top